181 related articles for article (PubMed ID: 35189618)
1. Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway.
Nakamoto K; Tokuyama S
Pharmacology; 2022; 107(5-6):330-338. PubMed ID: 35189618
[TBL] [Abstract][Full Text] [Related]
2. DHA supplementation prevent the progression of NASH via GPR120 signaling.
Nakamoto K; Shimada K; Harada S; Morimoto Y; Hirasawa A; Tokuyama S
Eur J Pharmacol; 2018 Feb; 820():31-38. PubMed ID: 29221950
[TBL] [Abstract][Full Text] [Related]
3. [Involvement of the Free Fatty Acid Receptor GPR120/FFAR4 in the Development of Nonalcoholic Steatohepatitis].
Nakamoto K; Tokuyama S
Yakugaku Zasshi; 2019; 139(9):1169-1175. PubMed ID: 31474633
[TBL] [Abstract][Full Text] [Related]
4. Enzymatically-epoxidized docosahexaenoic acid, 19,20-EpDPE, suppresses hepatic crown-like structure formation and nonalcoholic steatohepatitis fibrosis through GPR120.
Aoki H; Isobe Y; Yoshida M; Kang JX; Maekawa M; Arita M
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Mar; 1868(3):159275. PubMed ID: 36566874
[TBL] [Abstract][Full Text] [Related]
5. Autocrine negative feedback regulation of lipolysis through sensing of NEFAs by FFAR4/GPR120 in WAT.
Husted AS; Ekberg JH; Tripp E; Nissen TAD; Meijnikman S; O'Brien SL; Ulven T; Acherman Y; Bruin SC; Nieuwdorp M; Gerhart-Hines Z; Calebiro D; Dragsted LO; Schwartz TW
Mol Metab; 2020 Dec; 42():101103. PubMed ID: 33091626
[TBL] [Abstract][Full Text] [Related]
6. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
Depner CM; Philbrick KA; Jump DB
J Nutr; 2013 Mar; 143(3):315-23. PubMed ID: 23303872
[TBL] [Abstract][Full Text] [Related]
7. Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes.
On S; Kim HY; Kim HS; Park J; Kang KW
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31142011
[TBL] [Abstract][Full Text] [Related]
8. In vivo activation of leukocyte GPR120/FFAR4 by PUFAs has minimal impact on atherosclerosis in LDL receptor knockout mice.
Shewale SV; Brown AL; Bi X; Boudyguina E; Sawyer JK; Alexander-Miller MA; Parks JS
J Lipid Res; 2017 Jan; 58(1):236-246. PubMed ID: 27811230
[TBL] [Abstract][Full Text] [Related]
9. GPR120 protects lipotoxicity-induced pancreatic β-cell dysfunction through regulation of PDX1 expression and inhibition of islet inflammation.
Wang Y; Xie T; Zhang D; Leung PS
Clin Sci (Lond); 2019 Jan; 133(1):101-116. PubMed ID: 30523046
[TBL] [Abstract][Full Text] [Related]
10. Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis.
Lu Z; Li Y; Li AJ; Syn WK; Wank SA; Lopes-Virella MF; Huang Y
PLoS One; 2022; 17(11):e0277251. PubMed ID: 36331958
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
Lytle KA; Wong CP; Jump DB
PLoS One; 2017; 12(4):e0173376. PubMed ID: 28422962
[TBL] [Abstract][Full Text] [Related]
12. Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-κB and MAPK pathways and activating the Nrf2 pathway in mice.
Li J; Deng X; Bai T; Wang S; Jiang Q; Xu K
Int Immunopharmacol; 2020 Nov; 88():106961. PubMed ID: 33182038
[TBL] [Abstract][Full Text] [Related]
13. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.
Suckow AT; Polidori D; Yan W; Chon S; Ma JY; Leonard J; Briscoe CP
J Biol Chem; 2014 May; 289(22):15751-63. PubMed ID: 24742677
[TBL] [Abstract][Full Text] [Related]
14. Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M.
Liu H; Li N; Kuang G; Gong X; Wang T; Hu J; Du H; Zhong M; Guo J; Xie Y; Xiang Y; Wu S; Yuan Y; Yin X; Wan J; Li K
Free Radic Biol Med; 2024 Jan; 210():42-53. PubMed ID: 37984750
[TBL] [Abstract][Full Text] [Related]
15. Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.
Liu XJ; Xie L; Du K; Liu C; Zhang NP; Gu CJ; Wang Y; Abdelmalek MF; Dong WY; Liu XP; Niu C; Yang C; Diehl AM; Wu J
Liver Int; 2020 Apr; 40(4):830-843. PubMed ID: 31903720
[TBL] [Abstract][Full Text] [Related]
16. Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload.
Murphy KA; Harsch BA; Healy CL; Joshi SS; Huang S; Walker RE; Wagner BM; Ernste KM; Huang W; Block RC; Wright CD; Tintle N; Jensen BC; Wells QS; Shearer GC; O'Connell TD
Cardiovasc Res; 2022 Mar; 118(4):1061-1073. PubMed ID: 33752243
[TBL] [Abstract][Full Text] [Related]
17. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.
Oh DY; Walenta E; Akiyama TE; Lagakos WS; Lackey D; Pessentheiner AR; Sasik R; Hah N; Chi TJ; Cox JM; Powels MA; Di Salvo J; Sinz C; Watkins SM; Armando AM; Chung H; Evans RM; Quehenberger O; McNelis J; Bogner-Strauss JG; Olefsky JM
Nat Med; 2014 Aug; 20(8):942-7. PubMed ID: 24997608
[TBL] [Abstract][Full Text] [Related]
18. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
19. RLA8-A New and Highly Effective Quadruple PPAR-
Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
